Current Cancer Therapy Reviews

Journal Impact Factor: 0.9
Scopus Cite Score: 1.0

Indexed in: Scopus, ESCI, JCR

View All
Aims and Scope:
Current Cancer Therapy Reviews publishes full-length review/mini-reviews, original research articles, drug clinical trial studies and guest-edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal aims to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in the field of cancer therapy. It covers papers related to prevention, diagnosis and treatment of all types of cancers through biomarkers testing, biopsy, chemotherapy, hormone therapy, gene therapy, hyperthermia, immunotherapy, irreversible electroporation, laser therapy, photodynamic therapy, radiation therapy, radiotherapy and stem cell transplantation.
Read more...

Editor-in-Chief:

  • Yangchao Chen School of Biomedical Sciences
    Faculty of Medicine
    The Chinese University of Hong Kong
    Shatin
    Hong Kong

ISSN: 1573-3947 (Print)

eISSN: 1875-6301 (Online)

Special Issues With Active Call for Papers

Submission closes on: Mar 27, 2027
Precision Oncology in the Era of Biotechnology

The convergence of biotechnology innovations and precision medicine is transforming cancer care. Advanced biotechnological tools—including next-generation sequencing, CRISPR-based technologies, AI-driven diagnostics, engineered therapeutics (CAR-T, TCR-T, antibody-drug conjugates), and multi-omics profiling—are enabling unprecedented tumor characterization and personalized treatment strategies. This thematic issue will explore how biotechnology is reshaping precision oncology from bench to bedside, addressing diagnostic innovations, therapeutic breakthroughs, clinical implementation challenges, and future directions in making precision oncology accessible and effective for all patients. see more

Submission closes on: Oct 23, 2026
Current Status of Regulatory T Cells in Tumor Immune Escape and Immunotherapy

Regulatory T cells (Tregs) are a class of immunoregulatory suppressor cells characterized by the expression of CD4, CD25, and the transcription factor Forkhead box P3 (Foxp3). It plays an important role in maintaining immune homeostasis and inducing immune tolerance, and its dysfunction directly leads to the imbalance of immune homeostasis. In the tumor microenvironment (TME), traditional T cells can be induced and differentiated into Tregs. Tregs have a strong immunosuppressive function, inhibit anti-tumor immunity, and... see more